Twitter
  • "If you're a victim of domestic abuse, work is your safe place and being at home is not" Former Prime Minister… https://t.co/UtvqNWSKYu
  • If you are suffering in an abusive relationship, know that you are not alone. What you are going through is not you… https://t.co/zt48Rci7hl
  • The Domestic Abuse Bill will be a big step forward but it’s essential we seize the opportunity to go even further.… https://t.co/nDiTf7F2qL
  • Today we remember all those who lost their lives at Grenfell Tower. My thoughts are with the bereaved & survivors w… https://t.co/VndgjeJ61u
  • Today marks 3 years since the terror attack at Manchester Arena - a despicable act of hatred which targeted the you… https://t.co/9JHUJz5Imp
News

Theresa May welcomes COVID-19 vaccine trials in the Thames Valley

  • 6 Apr 2020

Theresa May MP praises the work of University of Oxford researchers who are part of an unprecedented vaccine development effort to prevent COVID-19 and welcomes the move to screen healthy volunteers for their upcoming vaccine trial in the Thames Valley Region.

Researchers from the University of Oxford are looking for up to 510 healthy volunteers aged between 18 – 55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19. The trial will provide valuable information on the safety aspects of the vaccine, as well as its ability to generate an immune response against the virus. Interested individuals can volunteer to participate on the COVID-19 vaccine website: https://covid19vaccinetrial.web.ox.ac.uk/volunteer

Mrs May said: ‘I welcome the determination and effort from researchers into finding a vaccine for COVID-19 which, if successful, would ultimately save tens of thousands of lives worldwide. The team at Oxford have been working hard on developing a vaccine since early January. They are looking for healthy volunteers from our area. Could you be one?  Volunteering could bring a vaccine against COVID-19 closer for us all.’

The trial has been approved by UK regulators and ethical reviewers. Researchers are working as quickly as possible to get the vaccine ready to be used in the trial, which includes further preclinical investigations and production of a larger number of doses of the vaccine.